TransMedics Group (NASDAQ:TMDX) Stock Rating Reaffirmed by Piper Sandler

TransMedics Group (NASDAQ:TMDX)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Sandler in a research report issued on Monday, Benzinga reports. They currently have a $180.00 price objective on the stock. Piper Sandler’s target price would suggest a potential upside of 30.32% from the stock’s previous close.

Several other analysts also recently commented on the stock. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Oppenheimer raised their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Robert W. Baird assumed coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price target on the stock. Needham & Company LLC assumed coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective on the stock. Finally, Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $174.30.

TransMedics Group Trading Up 3.0 %

NASDAQ:TMDX opened at $138.12 on Monday. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The stock’s 50 day simple moving average is $155.92 and its two-hundred day simple moving average is $134.97.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) EPS. As a group, analysts anticipate that TransMedics Group will post 1.22 earnings per share for the current year.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the sale, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the transaction, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,205 shares of company stock valued at $10,089,374. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently modified their holdings of the stock. Fidelis Capital Partners LLC bought a new stake in TransMedics Group in the first quarter worth $35,000. International Assets Investment Management LLC bought a new position in TransMedics Group in the 2nd quarter valued at $47,000. J.Safra Asset Management Corp lifted its holdings in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC boosted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.